CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6032 result(s)

indacaterol /mometasone furoate (Atectura Breezhaler)

Last Updated: May 26, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: indacaterol /mometasone furoate
Indications: Asthma maintenance (adults, children 12 or older)

  • Brand Name: Atectura Breezhaler
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0646-000
  • Project Status: Received
  • Submission Type: New

dupilumab (Dupixent)

Last Updated: May 25, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: dupilumab
Indications: atopic dermatitis

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0636-000
  • Project Status: Active
  • Submission Type: New

sacubitril/valsartan (Entresto)

Last Updated: May 26, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: sacubitril/valsartan
Indications: Heart failure, NYHA Class II or III

  • Brand Name: Entresto
  • Manufacturer: Novartis Pharma Inc.
  • Project Number: SR0644-000
  • Project Status: Received
  • Submission Type: Resubmission

icosapent ethyl (Vascepa)

Last Updated: May 26, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: icosapent ethyl
Indications: Ischemic events in statin-treated patients

  • Brand Name: Vascepa
  • Manufacturer: HLS Therapeutics
  • Project Number: SR0619-000
  • Project Status: Active
  • Submission Type: New

belimumab (Benlysta )

Last Updated: May 26, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: Belimumab
Indications: systemic lupus erythematosus

  • Brand Name: Benlysta
  • Manufacturer: GlaxoSmithKline Inc.
  • Project Number: SR0616-000
  • Project Status: Active
  • Submission Type: New

onasemnogene abeparvovec (Zolgensma)

Last Updated: May 26, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: onasemnogene abeparvovec
Indications: Spinal muscular atrophy (SMA), pediatrics

  • Brand Name: Zolgensma
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SG0649-000
  • Project Status: Pending
  • Submission Type: New